21:34 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

GLPG1837: Ph II SAPHIRA 1 data

Top-line data from 26 CF patients with the G551D mutation in the open-label, international Phase II SAPHIRA 1 trial showed that twice-daily oral GLPG1837 significantly reduced mean sweat chloride levels from 98 mmol/L at baseline...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
11:40 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

GLPG1837: Phase IIa SAPHIRA 2 data

Data from 7 patients with S1251N mutation-positive CF in the open-label, international Phase IIa SAPHIRA 2 trial showed that twice-daily oral GLPG1837 was generally well tolerated with no serious adverse events reported. Patients received twice-daily...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Clinical News

ABBV-974: Phase II started

Galapagos began the open-label, international Phase II SAPHIRA 1 trial to evaluate 3 doses of oral GLPG1837 twice daily for 4 weeks in >=12 patients with the G551D mutation. Last month, the company began the...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

ABBV-974: Phase II started

Galapagos began the open-label, international Phase II SAPHIRA 2 trial to evaluate 2 doses of twice-daily oral GLPG1837 for 4 weeks in >=6 patients with the S1251N mutation. The company said it expects to start...
08:00 , Jan 11, 2016 |  BioCentury  |  Strategy

Growing up Galapagos

With a new partner for filgotinib, Galapagos N.V. is poised to enter Phase III testing for the first time, after a five-year period of Phase II disappointments and scuttled deals. The new deal with Gilead...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

ABBV-974: Phase I data

A double-blind, placebo-controlled, Belgian Phase I trial in about 64 healthy volunteers showed that single doses of 30-2,000 mg oral GLPG1837 and twice-daily 125-800 mg doses of oral GLPG1837 for 14 days were generally well...
07:00 , Mar 23, 2015 |  BioCentury  |  Product Development

Galapagos' evolution inflection

Data next month for filgotinib will be the first near-term opportunity for Galapagos N.V. to show it can complete its shift from hybrid discovery/service company into a product-focused play. The Janus kinase-1 (JAK-1) inhibitor will...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

ABBV-974: Phase I started

Galapagos began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate single and multiple ascending doses of once-daily oral GLPG1837 in at least 40 healthy volunteers. The start of the trial triggered a $10 million...